Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published Date: May 15, 2025

Abstract

PURPOSE: The management of chronic lymphocytic leukemia (CLL) has significantly improved with targeted therapies. However, many patients experience a suboptimal response. To optimally select the best therapy, predictive biomarkers are necessary. In this study, we used the phosphoinositide 3-kinase (PI3K) inhibitor umbralisib as a model to (i) understand the impact of targeted treatment on cell signaling and immunophenotypes in responders and nonresponders, (ii) identify molecular features that predict individual treatment responses, and (iii) suggest alternative treatment options for the nonresponders.

Authors

  • Yanping Yin
    Department of Cardiology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Dongdu Road, Linhai, Zhejiang Province, 317000, China.
  • Haifeng Xu
  • Liye He
    University of Helsinki, Helsinki, Finland.
  • Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Anthony R Mato
    Memorial Sloan Kettering Cancer Center, New York, New York.
  • Tero Aittokallio
    Institute for Molecular Medicine Finland (FIMM), University of Helsinki, FI-00290 Helsinki, Finland.
  • Sigrid S Skånland
    Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Keywords

External Resources

Popular Topics
Recent Journals